{"nctId":"NCT02160145","briefTitle":"Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease","startDateStruct":{"date":"2014-05"},"conditions":["Chronic Kidney Disease","Autosomal Dominant Polycystic Kidney Disease"],"count":1370,"armGroups":[{"label":"Tolvaptan","type":"EXPERIMENTAL","interventionNames":["Drug: Tolvaptan (OPC-41061)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tolvaptan (OPC-41061)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female subjects with eGFR between 25-65 mL/min/1.73m2 (if aged 18 to55) or eGFR between 25-44 mL/min/1.73m2 (if aged 56 to \\<66)\n* Tolvaptan naÃ¯ve\n* Diagnosis of ADPKD by modified pei-Ravine criteria 1) 3 cysts per kidney by sonography or 5 cysts by CT or MRI with family history of ADPKD or 2) 10 cysts per kidney by any radiologic method and exclusion of other cystic kidney diseases if without family history\n\nExclusion Criteria:\n\n* Women of childbearing potential who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days after the last dose of Investigational medicinal product (IMP)\n* Women who are breast-feeding and/or who have a positive pregnancy test prior to receiving IMP\n* Need for chronic diuretic use\n* Hepatic impairment or liver function abnormalities other than that expected for ADPKD with typical cystic liver disease\n* Advanced diabetes, evidence of additional significant renal disease, renal cancer, single kidney, recent renal surgery or acute kidney injury\n* Contraindications to required trial assessments\n* Medical history or medical findings inconsistent with safety or compliance with trial assessments","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Mean Annualized Change in eGFR From Pretreatment Baseline to Post-treatment Follow-up.","description":"The mean annualized change in eGFR was calculated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula from pretreatment baseline to post-treatment follow-up, annualized (divided) by each subject's trial duration.\n\nThe baseline for the primary endpoint was defined as the average of up to 3 eGFR values observed during the screening and placebo run-in periods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.339","spread":"0.240"},{"groupId":"OG001","value":"-3.610","spread":"0.240"}]}]}]},{"type":"SECONDARY","title":"Mean Annualized Slope of eGFR Change","description":"To compare the efficacy of tolvaptan treatment in reducing the decline of annualized eGFR slope, as compared with placebo, in subjects with late-stage CKD due to ADPKD who tolerated tolvaptan during an initial run-in period, the annualized rate of eGFR change was derived from each individual subject's eGFR slope using the CKD-EPI formula.\n\nThe annualized eGFR change slope was derived from all eGFR observations from placebo-run-in, tolvaptan run-in, double-blind treatment and post-treatment follow-up periods using the linear mixed model of analysis. The mean annualized slope of eGFR change is presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.160","spread":"0.140"},{"groupId":"OG001","value":"-4.170","spread":"0.142"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up","description":"The mean change from baseline in urine osmolality for the double-blind treatment period collection timepoints and post-treatment follow-up are presented. Baseline was defined as the last evaluation prior to post-randomization dosing.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":"80.3"},{"groupId":"OG001","value":"177.7","spread":"124.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":"84.3"},{"groupId":"OG001","value":"179.1","spread":"126.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":"92.1"},{"groupId":"OG001","value":"179.9","spread":"125.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.9","spread":"96.0"},{"groupId":"OG001","value":"180.3","spread":"121.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"162.4","spread":"114.0"},{"groupId":"OG001","value":"179.5","spread":"128.9"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Change From Baseline in Urine Specific Gravity During the Double-blind Treatment Period and Post-treatment Follow-up","description":"The mean change from baseline in urine specific gravity for the double-blind treatment period collection timepoints and post-treatment follow up are presented. Baseline was defined as the last evaluation prior to post-randomization dosing.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0001","spread":"0.0022"},{"groupId":"OG001","value":"0.0041","spread":"0.0033"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0003","spread":"0.0024"},{"groupId":"OG001","value":"0.0042","spread":"0.0033"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.004","spread":"0.0025"},{"groupId":"OG001","value":"0.0040","spread":"0.0032"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0006","spread":"0.0027"},{"groupId":"OG001","value":"0.0040","spread":"0.0033"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0037","spread":"0.0031"},{"groupId":"OG001","value":"0.0040","spread":"0.0034"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":43,"n":1491},"commonTop":["Polyuria","Thirst","Nocturia","Renal pain","Viral upper respiratory tract infection"]}}}